Indapta is a privately-held company focused on developing and bringing to market a diverse pipeline of cell therapies to treat the still unmet medical needs of patients with blood and solid-tumor cancers as well as autoimmune diseases. The company's proprietary robust platform of naturally-occurring g-NK cells is specifically designed to create best-in-class, highly potent, more accessible, and scalable cell therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/17/24 | $22,500,000 | Venture |
Leaps by Bayer Myeloma Investment Fund Pontifax RA Capital Management Vertex Ventures | undisclosed |
